Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes

Journal of Virology

Volumn 72, Issue 9, 1998, Pages 7099-7107

  Park, Eun Ju ^a   Vujcic, Luba K ^b   Anand, Rita ^b,d   Theodore, Theodore S ^c   Quinnan Jr , Gerald V ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41;

AMINO ACID SEQUENCE; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS GENE; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

EID: 0031846519     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.9.7099-7107.1998     Document Type: Article

References (79)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Back, N. K. T., L. Smit, M. Schutten, P. L. Nara, M. Tersmette, and J. Goudsmit. 1993. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J. Virol. 67:6897-6902.
3. Barnes, W. M. 1992. The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion. Gene 112:29-35.
4. Broliden, P., A. von Gegerfelt, P. Clapham, J. Rosen, E. Fenyo, B. Wahren, and K. Broliden. 1992. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. USA 89:471-475.
5. Cariello, N. F., J. A. Swenberg, and T. R. Skopek. 1991. Fidelity of Thermococcus litoralis DNA polymerase (Vent) in PCR determined by denaturing gradient gel electrophoresis. Nucleic Acids Res. 19:4193-4198.
6. Carrow, E. W., L. K. Vujcic, W. L. Glass, K. B. Seamon, S. C. Rastogi, R. M. Hendry, R. Boulos, N. Bzila, and G. V. Quinnan. 1991. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Res. Hum. Retroviruses 7:831-838.
7. Chamat, S., P. Nara, L. Berquist, A. Whalley, W. J. M. Morrow, H. Kohler, and C.-Y. Kang. 1992. Two major groups of neutralizing anti-gp120 antibodies exist in HIV infected individuals. J. Immunol. 149:645-654.
8. Chen, C.-H., T. J. Matthews, C. B. McDanal, D. P. Bolognesi, and M. L. Greenberg. 1995. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV fusion activity of gp41 derivatives: implications for viral fusion. J. Virol. 69:3771-3777.
9. Coffin, J. 1986. Genetic variation in AIDS viruses. Cell 46:1-4.
10. Conner, R. I., K. E. Sheridan, C. Lai, L. Zhang, and D. D. Ho. 1996. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 70: 5306-5311.
11. Dawson, M. 1980. Maedi/visna: a review. Vet. Rec. 106:212-216.
12. Delwart, E. L., G. Mosialos, and T. Gilmore. 1990. Retroviral envelope glycoproteins contain a leucine zipper-like repeat. AIDS Res. Hum. Retroviruses 6:703-706.
13. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, N. R. Landau. 1996. Identification of a major coreceptor for primary isolates of HIV-1. Nature 381:661-666.
14. Englund, G., M. Hoggan, T. Theodore, and M. A. Martin. 1991. A novel HIV-1 isolate containing alterations affecting the NF-κB element. Virology 181:150-157.
15. Fauci, A. S., and P. J. Fishinger. 1988. The development of an AIDS vaccine: progress and promise. Public Health Rep. 103:230-236.
16. Freed, E. O., and M. Martin. 1994. Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J. Virol. 68:2503-2512.
17. Fung, M. S. C., C. R. Y. Sun, W. L. Gordon, R.-S. Liou, T. W. Chang, W. N. C. Sun, E. S. Daar, and D. D. Ho. 1992. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:848-856.
18. Fung, M. S. C., C. Sun, N. C. Sun, N. Y. Chang, and T. W. Chang. 1987. Monoclonal antibodies that neutralize HIV-1 virions and inhibit syncytium formation by infected cells. Bio/Technology 5:940-946.
19. Gallaher, W. R., J. M. Ball, R. F. Garry, M. C. Griffin, and R. C. Montelaro. 1989. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retriviruses 5:431-438.
20. Goodenow, M., T. Huet, W. Saurin, S. Kwok, J. Sninsky, and S. Wain-Hobson. 1989. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J. Acquired Immune Defic. Syndr. 2:344-352.
21. Gurgo, C., H. G. Guo, G. Franchini, A. Aldovini, E. Collati, K. Farrel, F. Wong-Stahl, R. C. Gallo, and M. S. Reitz. 1988. Envelope sequences of two new United States HIV-1 isolates. Virology 164:531-536.
22. Haigwood, N. L., J. R. Shuster, G. K. Moore, H. Lee, P. V. Skiles, K. W. Higgins, P. J. Barr, C. George-Nascimento, and K. S. Steimer. 1990. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6:855-869.
23. 2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69: 6705-6711.
24. Higgins, D. G., and P. M. Sharp. 1989. Fast and sensitive multiple sequence alignment on a microcomputer. CABIOS 5:151-153.
25. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
26. Ho, D. D., M. S. C. Fung, Y. Cao, X. L. Li, C. Sun, T. W. Chang. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88:8949-8952.
27. Ho, D. D., T. Moudgil, and M. Alam. 1989. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321:1621-1625.
28. Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-74.
29. Javaherian, K., A. J. Langois, C. McDanal, K. L. Ross, L. I. Eckler, C. L. Jelĺs, A. T. Profy, J. R. Rusche, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1989. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 86:6768-6772.
30. Joag, S. V., E. B. Stephens, and O. Narayan. 1996. Lentiviruses, p. 1977-1996. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
31. Kalams, S. A., R. P. Johnson, M. J. Dynan, K. E. Hartman, T. Harrer, E. Harrer, A. K. Trocha, W. A. Blattner, S. P. Buchbinder, and B. D. Walker. 1996. T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J. Exp. Med. 183:1669-1679.
32. Karwowska, S., M. K. Gorny, A. Buchbinder, V. Gianakakos, C. Williams, T. Fuerst, and S. Zolla-Pazner. 1992. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retroviruses 8:1099-1106.
33. Katzenstein, D. A., L. K. Vujcic, A. Latif, R. Boulos, N. A. Halsey, T. C. Quinn, S. C. Rastogi, and G. V. Quinnan. (1990. Human immunodeficiency virus neutralizing antibodies in sera from North America and Africa. J. Acquired Immune Defic. Syndr. 3:810-816.
34. Kinsey, N. E., M. G. Anderson, T. J. Unangst, S. V. Joag, O. Narayan, M. C. Zink, and J. E. Clements. 1996. Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Virology 221:14-21.
35. Konno, S., and H. Yammamoto. 1970. Pathology of equine infectious anemia. Cornell Vet. 60:393-449.
36. Kono, Y., K. Kobayashi, and Y. Fukunaga. 1973. Antigenic drift of equine infectious anemia virus in chronically infected horses. Arch. Gesamte Virusforsch. 41:1-10.
37. Korber, B., S. Wolinsky, B. Haynes, K. Kunstman, R. Levy, M. Furtado, P. Otto, and G. Myers. 1992. HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res. Hum Retroviruses 8:1461-1465.
38. Leder, P., D. Tiemeier, and L. Enquist. 1977. EK2 derivatives of bacteriophage lambda useful in the cloning of DNA from higher organisms: the Lambda gtWES system. Science 196:175-177.
39. Lennette, E. H. 1964. General principles underlying laboratory diagnosis of viral and rickettsial infections, p. 45. In E. H. Lennette and M. J. Schmidt (ed.), Diagnostic procedures of viral and rickettsial diseases. American Public Health Association, New York, N.Y.
40. Letvin, N. 1993. Vaccines against human immunodeficiency virus - progress and prospects. N. Engl. J. Med. 329:1400-1405.
41. Levy, J. A. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:183-289.
42. Liou, H.-C., W. C. Sha, M. L. Scott, and D. Baltimore. 1994. Sequential induction of NF-κB/Rel family proteins during B-cell terminal differentiation. Mol. Cell. Biol. 14:5349-5359.
43. + T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 69:3712-3720.
44. Matsushita, S., M. Robert-Guroff, J. Rusche, A. Koito, T. Hattori, H. Hoshino, K. Javaherian, C. Jellis, K. Takatsuki, and S. Putney. 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62:2107-2114.
45. McKeating, J. A., J. Gow, J. Goudsmit, L. H. Pearl, C. Mulder, and R. A. Weiss. 1989. Characterization of HIV-1 neutralization escape mutants. AIDS 3:777-784.
46. McKeating, J. A., C. Schotton, J. Cordell, S. Graham, P. Balfe, N. Sullivan, M. Charles, M. Page, A. Bolmstedt, S. Olofsson, S. C. Kayman, Z. Wu, A. Pinter, C. Dean, J. Sodroski, and R. A. Weiss. 1993. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 67:4932-4944.
47. Modrow, S., B. H. Hahn, G. M. Shaw, R. C. Gallo, F. Wong-Staal, and H. Wolf. 1987. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J. Virol. 61:570-578.
48. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
49. Moore, J. P., Q. J. Sattentau, H. Yoshiyama, M. Thali, M. Charles, N. Sullivan, S.-W. Poon, M. S. Fung, F. Traincard, M. Pinkus, G. Robey, J. E. Robinson, D. D. Ho, and J. Sodroski. 1993. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J. Virol. 67:6136-6151.
50. Mullis, K. B., and F. A. Faloona. 1987. Specific synthesis of DNA in vitro via a polymerase catalyzed chain reaction. Methods Enzymol. 255:335-350.
51. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
52. Myers, G., J. A. Berzofsky, B. Korber, R. F. Smith, and G. N. Pavlakis. 1993. Human retroviruses and AIDS 1992. Los Alamos National Laboratory, Los Alamos, N. Mex.
53. Nakamura, G. R., R. Byrn, D. M. Wilkes, J. A. Fox, M. R. Hobbs, R. Hastings, H. C. Wessling, M. A. Norcross, B. M. Fendly, and P. W. Berman. 1993. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J. Virol. 67:6179-6191.
54. Nara, P. L., L. Smit, N. Dunlop, W. Hatch, M. Merges, D. Waters, J. Kelliher, R. C. Gallo, P. J. Fischinger, and J. Goudsmit. 1990. Emergence of viruses resistant to neutralization by V3 specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol. 64:3779-3791,
55. Narayan, O., D. E. Griffin, and J. Chase. 1977. Antigenic drift of visna virus in persistently infected sheep. Science 197:376-378.
56. Nixon, D. F., K. Broliden, G. Ogg, and P. A. Broliden. 1992. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 76:515-534.
57. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271:1582-1586.
58. Quinnan, G. V., P. F. Zhang, D. W. Fu, M. Dong, and J. B. Margolick. Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in Multicenter AIDS Cohort Study participants. AIDS Res. Hum. Retroviruses, in press.
59. Quinnan, G. V., Jr. 1997. Immunization against viral diseases, p. 791-833. In G. Galasso, T. C. Merigan, and R. Whitley (ed.), Antiviral agents and viral diseases of man. Raven Press, Philadelphia, Pa.
60. Reitz, M. S., C. Wilson, C. Naugle, R. C. Gallo, and M. Robert-Guroff. 1988. Generation of a neutralization resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54:57-63.
61. Robert-Guroff, M., M. S. Reitz, W. G. Robey, and R. C. Gallo. 1986. In vitro generation of an HTLV-III variant by neutralizing antibody. J. Immunol. 137:3306-3309.
62. Sawyer, L. A., D. A. Katzenstein, R. M. Hendry, E. J. Boone, L. K. Vujcic, C. C. Williams, S. L. Zeger, A. J. Saah, C. R. Rinaldo, Jr., J. P. Phair, J. V. Giorgi, and G. V. Quinnan, Jr. 1990. Possible beneficial effects of neutralizing antibodies and antibody-dependent cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6:341-356.
63. Shugars, D. C., C. T. Wild, T. Greenwell, and T. J. Matthews. 1996. Biophysical characterization of recombinant proteins expressing the leucine zipper like domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 70:2982-2991.
64. Skinner, M. A., R. Ting, A. J. Langlois, K. J. Weinhold, H. K. Lyerly, K. Jahaverian, and T. J. Matthews. 1988. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res. Hum. Retroviruses 4:187-197.
65. Stuve, L. L., S. Brown-Shimer, C. Pachl, R. Naharian, D. Diaz, and R. L. Burke. 1987. Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene. J. Virol. 61:326-335.
66. Sutton, R. E., and D. R. Littman. 1996. Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system. J. Virol. 70:7322-7326.
67. Takeda, A., J. E. Robinson, D. D. Ho, C. Debouck, N. L. Haigwood, and F. A. Ennis. 1992. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120. J. Clin. Invest. 89:1952-1957.
68. Thali, M., M. Charles, C. Furman, L. Cavacini, M. Posner, J. Robinson, and J. Sodroski. 1994. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J. Virol. 68:674-680.
69. Thali, M., C. Furman, D. D. Ho, J. Robinson, S. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66:5635-5641.
70. Thali, M., J. P. Moore, C. Furman, M. Charlis, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
71. Theodore, T. S., G. Englund, A. Buckler-White, C. E. Buckler, M. A. Martin, and K. W. C. Peden. Construction and characterization of a stable full-length cacrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res. Hum. Retroviruses 12:191-194.
72. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivassan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
73. Vujcic, L. K., D. H. Shepp, M. Klutch, M. A. Wells, R. M. Hendry, A. E. Wittek, L. Krilov, and G. V. Quinnan. 1988. Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J. Infect. Dis. 157:1047-1050.
74. Vujcic, L. K., and G. V. Quinnan, Jr. 1995. Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res. Hum. Retroviruses 11:783-787.
75. Watkins, B. A., S. Buge, K. Aldrich, A. E. Davis, J. Robinson, M. S. Reitz, Jr., and M. Robert-Guroff. 1996. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J. Virol. 70:8431-8437.
76. Wilson, C., M. S. Reitz, K. Aldrich, P. J. Klasse, J. Blomberg, R. C. Gallo, and M. Robert-Guroff. 1990. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J. Virol. 64:3240-3248.
77. Wyatt, R. W., N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, M. Posner, and J. Sodroski. 1993. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557-4565.
78. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.
79. Zwart, G., H. Langeduk, L. Van der Hoek, D. J. Jean-Jacques, T. F. W. Wolfs, C. Ramautarsing, M. Bakker, A. De Rinde, and J. Goudsmit. 1991. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 181:481-189.